Fig. 2: Survival outcomes for standard-risk and high-risk patients treated with RVd versus D-RVd. | Blood Cancer Journal

Fig. 2: Survival outcomes for standard-risk and high-risk patients treated with RVd versus D-RVd.

From: Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

Fig. 2: Survival outcomes for standard-risk and high-risk patients treated with RVd versus D-RVd.

A Progression-free survival for standard-risk NDMM patients treated with D-RVd versus RVd. B Progression-free survival for high-risk NDMM patients treated with D-RVd versus RVd. C Overall survival for standard-risk NDMM patients treated with D-RVd versus RVd. D Overall survival for high-risk NDMM patients treated with D-RVd versus RVd.

Back to article page